|Ms. Lisa A. Conte||Founder, CEO, Pres & Director||529.01k||N/A||1959|
|Dr. Steven R. King||Exec. VP of Sustainable Supply, Ethnobotanical Research & Intellectual Property and Sec.||323.36k||N/A||1958|
|Ms. Carol R. Lizak||Chief Accounting Officer, VP of Fin. & Corp. Controller||N/A||N/A||1964|
|Dr. Pravin R. Chaturvedi||Chair of Scientific Advisory Board & Acting Chief Scientific Officer||N/A||N/A||1963|
|Mr. Jonathan S. Wolin||Chief Compliance Officer & Corp. Counsel||N/A||N/A||N/A|
Jaguar Health, Inc., a commercial stage natural-products pharmaceuticals company, focuses on developing gastrointestinal products for human prescription use and animals worldwide. The company, through its wholly-owned subsidiary, Napo Pharmaceuticals, Inc., focuses on developing and commercializing proprietary human gastrointestinal pharmaceuticals for the global marketplace from plants used traditionally in rainforest areas. Its human health product pipelines include Mytesi, which is Phase II clinical trial for the treatment of cancer therapy-related diarrhea, as well as for the supportive care for inflammatory bowel disease; formulation of crofelemer that is Phase II clinical trial for the treatment of short bowel syndrome, congenital diarrheal disorders, and irritable bowel syndrome - diarrhea predominant diseases; and SB-300, a second-generation anti-secretory agent for multiple indications, including cholera. The company's animal health product candidates comprise Canalevia, an animal prescription drug product candidate intended for treatment of various forms of diarrhea in dogs; and Equilevia is Jaguar's non-prescription product for total gut health in equine athletes. In addition, the company's products include Neonorm Calf and Neonorm Foal. Jaguar Health, Inc. is headquartered in San Francisco, California.
Jaguar Health, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.